Yongqian Shu

机构：Nanjing Medical University · ORCID：0000-0003-3122-7139

发表论文 208 篇 · 总被引 9452 次 · h-index 52

代表论文

• Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial (2024 · Nature Medicine · 被引 130)
• Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC (2023 · Nature Cancer · 被引 35)
• CBX4 counteracts cellular senescence to desensitize gastric cancer cells to chemotherapy by inducing YAP1 SUMOylation (2024 · Drug Resistance Updates · 被引 27)
• Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial (2023 · Signal Transduction and Targeted Therapy · 被引 18)
• A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice (2024 · The Oncologist · 被引 11)
• Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials (2024 · Medicine · 被引 2)